Key result
Furosemide 80 mg/mL SC demonstrated equivalent bioavailability to furosemide 80 mg IV (LSMR AUC inf 107.3%; 90% CI 103.9%-110.8%), with consistent diuresis, natriuresis, and kaliuresis.
Why the study?
Furosemide 80 mg/mL is a novel concentrated formulation administered as a single 1.0-mL subcutaneous injection that could improve convenience compared with an existing 5-hour subcutaneous infusion.
Does a single subcutaneous injection of furosemide 80 mg/mL provide equivalent bioavailability and pharmacodynamics compared to intravenous furosemide in healthy volunteers?
RCT (n=21)
Open-label
1:1
Does a single subcutaneous injection of furosemide 80 mg/mL provide equivalent bioavailability and pharmacodynamics compared to intravenous furosemide in healthy volunteers?
A novel 80 mg/mL subcutaneous formulation of furosemide demonstrated equivalent bioavailability and consistent diuresis, natriuresis, and kaliuresis compared to intravenous furosemide in healthy volunteers.
May support SC furosemide as IV alternative for decongestion; leaves open efficacy confirmation in larger HF outcome trials.
Pharmacodynamics a b s t r a c tPurpose: Furoscix (furosemide injection) 80 mg/10 mL is a pH neutral formulation administered subcutaneously (SC) over 5 hours to treat edema in adults with chronic HF or chronic kidney disease.Furosemide 80 mg/mL is a novel concentrated formulation administered as a single 1.0-mL SC injection that could improve convenience for patients.This randomized, open-label, phase 1 study assessed the pharmacokinetics, bioavailability, pharmacodynamics, and safety of furosemide 80 mg/mL SC versus furosemide 80 mg administered intravenously (IV).Methods: Healthy volunteers were randomized 1:1 to furosemide 80 mg/mL SC or furosemide 80 mg IV (two 40-mg boluses, 2 hours apart), and after a 3-day washout, received the opposite treatment.Plasma furosemide pharmacokinetics, urine output, and urinary sodium and potassium excretion were measured through 12 hours post-dose.Bioavailability (the primary endpoint) was assessed as the least-squares mean ratio (LSMR) of area under the curve (AUC) from time 0-last (AUC last ) and 0-infinity (AUC inf ) between furosemide SC and furosemide IV.Plasma furosemide pharmacokinetics were assessed noncompartmentally.Pharmacodynamics were assessed using a repeated measures, mixed model analysis.Safety was assessed through end of study.Results: Twenty-one participants were randomized (furosemide SC/IV, n = 10; furosemide IV/SC, n = 11).The furosemide SC/IV LSMR (90% confidence interval [CI]) AUC last was 106.1% (102.7%,109.6%), and LSMR (90% CI) AUC inf was 107.3% (103.9%,110.8%).Furosemide 80 mg/mL SC had bioavailability equivalent to furosemide 80 mg IV, as the CIs fell within 80.0%-125.0%.Mean (SD) C max was 4532.9 (1497.7)ng/mL with furosemide 80 mg/mL SC and 10,087.6 (2804.7)ng/mL with furosemide IV.The therapeutic effects of furosemide 80 mg/mL SC on diuresis, natriuresis, and kaliuresis occurred within 1 hour of treatment and were consistent with those of furosemide IV at all time points.There was no significant difference between furosemide 80 mg/mL SC versus furosemide IV in total urine output or urinary sodium or potassium excretion at 0-6 hours, 0-8 hours, or 0-12 hours.Adverse events (AEs) occurred in 14 (66.7%)participants (furosemide SC, n = 11 [52.4%];furosemide IV, n = 7 [35.0%])and were mild or moderate.Ten (47.6%) participants had injection site AEs, all of which were treatment-related, mild, non-serious, and resolved.Injection site pain scores graded on a Likert 11-point scale remained low (mean, < 0.4; median, 0) at all time points, were similar between groups, and decreased over time.Conclusions: Furosemide 80 mg/mL SC injection was generally well tolerated and had bioavailability, diuresis, natriuresis, and kaliuresis consistent with those of furosemide IV.
No takes yet. Share an insight, caveat, or question.
Alcorn et al. (2025) conducted an RCT in Healthy volunteers (n=21). Furosemide vs. Furosemide 80 mg IV was evaluated on Bioavailability (least-squares mean ratio of AUC from time 0-last and 0-infinity) (LSMR 107.3%, 95% CI 103.9%-110.8%). Furosemide 80 mg/mL SC demonstrated equivalent bioavailability to furosemide 80 mg IV (LSMR AUC inf 107.3%; 90% CI 103.9%-110.8%), with consistent diuresis, natriuresis, and kaliuresis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: